From:  Understanding doxorubicin associated calcium remodeling during triple-negative breast cancer treatment: an in silico study

90% CI for Doxo 3 and Doxo 3 + drug parametric conditions

CasesParametric conditionsPeak amplitudePeak widthAUC
Doxo 375% ↑ in (β, γ, p1, p2, p3)[0.3373, 0.3390][19.2700, 19.3436][31.1452, 31.2368]
Doxo 3 + Pyr6Doxo 3 + 50% ↓ in β[0.3271, 0.3288][25.1828, 25.2654][24.9923, 25.0537]
Doxo 3 + linoleic acidDoxo 3 + 50% ↓ in β and γ[0.3348, 0.3365][24.3140, 24.3876][23.2118, 23.2662]
Doxo 3 + SKF96365Doxo 3 + 50% ↓ in β and γ[0.3348, 0.3365][24.3138, 24.3892][23.1945, 23.2495]
Doxo 3 + dantroleneDoxo 3 + 50% ↓ in p1[0.2122, 0.2133][25.8705, 25.9780][26.2765, 26.3655]
Doxo 3 + caffeineDoxo 3 + 50% ↓ in p1[0.2122, 0.2133][25.8709, 25.9809][26.2900, 26.3800]
Return to article view

↓: increase in the parameter value; ↑: decrease in the parameter value